Alkeon Capital Management
IGMS

Alkeon Capital Management’s IGM Biosciences IGMS Stock Holding History

Alkeon Capital Management’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-711,777
Closed -$9.78M – 122
2023
Q1 		$9.78M Sell
711,777
-121,464
-15% -$2.51M 0.02% 112
2022
Q4 		$14.2M Sell
833,241
-128,372
-13% -$2.57M 0.05% 111
2022
Q3 		$21.9M Sell
961,613
-72,422
-7% -$1.46M 0.07% 113
2022
Q2 		$18.6M Hold
1,034,035
– – 0.05% 116
2022
Q1 		$27.6M Buy
1,034,035
+95,000
+10% +$1.77M 0.06% 121
2021
Q4 		$27.5M Sell
939,035
-9,762
-1% -$485K 0.05% 120
2021
Q3 		$62.4M Sell
948,797
-102,632
-10% -$7.85M 0.11% 108
2021
Q2 		$87.5M Sell
1,051,429
-2,123
-0.2% -$157K 0.13% 107
2021
Q1 		$80.8M Buy
1,053,552
+2,568
+0.2% +$234K 0.12% 106
2020
Q4 		$92.8M Buy
1,050,984
+122,184
+13% +$8.59M 0.15% 101
2020
Q3 		$68.6M Buy
928,800
+175,000
+23% +$10.4M 0.13% 95
2020
Q2 		$55M Buy
753,800
+270,200
+56% +$16.4M 0.14% 96
2020
Q1 		$27.2M Buy
+483,600
New +$21.2M 0.12% 99

Other funds holding IGMS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Alkeon Capital Management's IGMS Position: Q2 2023 in Review

Alkeon Capital Management sold out of IGM Biosciences (IGMS) in Q2 2023, closing a stake of 711,777 shares — an estimated $9.78M sold.

Alkeon Capital Management first reported a position in IGMS in Q1 2020 and held it in 13 quarters. The position peaked at $92.8M in Q4 2020. 79 funds tracked by Wall St. Rank hold IGMS as of Q2 2023.

  • Alkeon Capital Management reported no remaining IGM Biosciences position as of Q2 2023 after selling out during the quarter.
  • Alkeon Capital Management sold 711,777 IGM Biosciences shares in Q2 2023, an estimated $9.78M.
  • Alkeon Capital Management first reported a position in IGM Biosciences in Q1 2020 and held it in 13 quarters.
  • Alkeon Capital Management's IGM Biosciences position peaked at $92.8M in Q4 2020.
  • 79 funds tracked by Wall St. Rank held IGM Biosciences as of Q2 2023.

Based on Alkeon Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.